We are delighted to announce that Cureus Founder and Editor-in-Chief Dr. John Adler was presented with the American Association of Neurological Surgeons’ Cushing Award for Technical Excellence and Innovation in Neurosurgery!
Presented at the 2018 AANS annual meeting in New Orleans on Monday April 30th, the Cushing Award could well be considered the Nobel Prize for Neurosurgery. The award was established in 2013 to honor innovation, skill and technical prowess in the development of new procedures which have become part of the arsenal neurosurgeons use to treat disease or trauma. John’s formative role in founding Cureus, “a disruptive platform for creating and sharing medical knowledge” was cited during the award presentation. Here at Cureus we are proud to call John our leader as his lifetime of professional accomplishments, including the creation of Cureus, led him to this point.
Founded by Harvey Cushing, after which the award is named, the 2018 AANS Annual Scientific Meeting is attended by neurosurgeons, neurosurgical residents, medical students, neuroscience nurses, clinical specialists, physician assistants, allied health professionals and other medical professionals, the AANS Annual Scientific Meeting is the largest gathering of neurosurgeons in the nation, with an emphasis on the field’s latest research and technological advances.
Allegations were recently leveled against iMed.pub, an organization affiliated with one of our channel partners, Internet Medical Society. We take such matters very seriously. We have conducted a thorough investigation and we’re here to share our thoughts on this situation as we move forward.
After considering the allegations and speaking at length with the IMS channel administrator, Manuel Menendez, we can state that we believe in the sincerity of IMS’s ambition to publish credible medical scientific articles. While the accusations are certainly nothing to take lightly, we feel confident that work being submitted to Cureus via the IMS channel is of suitable quality and repute. Furthermore, via our wholly unique post-publication review and scoring system, Cureus is in a unique position to uncover fraudulent and illegitimate science, as we actively encourage our community to examine and review articles long after they’ve passed through peer review.
It is worth reminding all readers of scientific publications to always interpret the content with a skeptical eye, whether the article is published in Nature, The New England Journal of Medicine or Cureus. Healthy skepticism is always at the heart of science. It is only through the lens of time that scientific ideas can be truly validated, which is why we at Cureus advocate for our process of post-publication review via SIQ.
As a result, Cureus will continue to host the Internet Medical Society channel and looks forward to the channel’s continued success. As has been the case since our launch in 2011, Cureus will not tolerate plagiarism or illegitimate or untoward publication practices and will remain ever-watchful for any signs of potential transgressions.
Dr. Laura Esserman, the principal investigator for the I-SPY adaptive studies and a contributing author to Cureus, has been working with Puma Biotechnology to assess neratinib for metastatic HER2-positive breast cancer. Why is this newsworthy, you say? Well, the I-SPY TRIAL is paving the way for accelerated regulatory review of new drug combinations, enabling potentially life-saving medicine to get to market faster than ever before.
This emphasis on accelerated efficiency and quality is similar to that of Cureus. We value speed and efficiency (although never at the expense of quality) in publishing important medical science and providing free access to this knowledge all across the world.
Many in the medical community have closely watched and waited for word on the study’s results, as the spotlight afforded by this research has shone brightly on both the I-SPY TRIAL and Dr. Esserman.
As a key contributor to Cureus, we couldn’t be prouder and more encouraged by these exciting developments made possible by all the hard work of Dr. Esserman and her team. And we’re not the only ones, as there has been plenty of positive media coverage as well, including this report on NBC Nightly News.
The good folks over at OncLive recently caught up with Dr. Esserman, and she had this to say regarding recent I-SPY 2 TRIAL:
If you’d like to learn more, there’s no better place to go than directly to the source – click here to check out the original journal article, A Model for Accelerating Identification and Regulatory Approval of Effective Investigational Agents, only on Cureus.